Bisdemethoxycurcumin re-expresses of ER-α through ILK inhibition is regulated by a pathway involving Twist andYB-1 in TNBC cells

• Main Authors: Chun-Chen Huang, 黃俊誠
• Other Authors: Tzong-Der Way 魏宗德
• Format: Others
• Language: zh-TW
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/x22cwt

碩士 === 中國醫藥大學 === 生物科技學系碩士班 === 102 === Malignant neoplasms have continued to be the top leading cause of death. Recently, breast cancer is most common malignancy among women in Taiwan and its incidence is increasing worldwide. Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer, it is defined by a lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. However, TNBC is a non-specific receptor expression and is therefore not suitable for use hormone therapy and target therapy,currently there is no specific clinical treatment. In this study, we used bisdemethoxycurcumin (BDMC), a natural derivative of curcumin to investigate the effects of BDMC on TNBC MDA-MB-231 cells. Interestingly, we showed that BDMC could re-express ER-α expression. Tamoxifen is one of the most widely used chemotherapeutic agents for the treatment of ER-positive breast cancer patients. Our study showed that BDMC enhanced the anticancer effect of tamoxifen through inducing apoptosis in TNBC cells.YB-1 isa known transcriptional regulator of ER-αexpression. BDMC could re-express ER-α through reducing the expression of YB-1 in TNBC cells. Moreover, we demonstrated that BDMC could decrease integrin-linkedkinase(ILK) and Twist expression that decrease expression of YB-1. These finding suggest BDMC will be a potential anticancer drug for TBNC.